$ENTB Stem Cell Working to Treat Pets Cancer/Arthritis
FORM 8-K - CURRENT REPORT
Zander Therapeutics is a Subsidiary of Entest Biomedical, Inc. - Regen BioPharma, Inc. (OTCQB:RGBP) is the Parent of Entest (ENTB-OTC)
RGBP has licensed various items to ENTB-NR2F6 being a Primary Focus.
NR2F6 is the Key to Zanders Success-Working Clinically to Treat Pets for Cancer/Arthritis - Thoroughbred Race Horses for (EIPH)
$ENTB has Shown Great Results - Silencing/Killing Cancer Cells Using Pets Own Blood
Great News -Further Advancement-Treating Cancer-Auto Immune Diseases-Lupus
Robert Kreh - Principal
Small Cap Solutions, LLC
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.